Insertional mutagenesis at positions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors with eliminated heparin-binding ability and introduced novel tropism

Human Gene Therapy

Volumn 17, Issue 3, 2006, Pages 353-361

  Shi, Xiangqun ^a   Fang, Guangguang ^b   Shi, Wenfang ^c,d  

^a LANZHOU GENERAL HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SHENZHEN UNIVERSITY   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; BETA GALACTOSIDASE; EPITOPE; HEPARIN; INTEGRIN RECEPTOR;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 2; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE INSERTION; GENE TARGETING; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; MUTAGENESIS; NONHUMAN; PARVOVIRUS VECTOR; TISSUE SPECIFICITY; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS GENE; VIRUS MUTANT; VIRUS RECOMBINANT;

ANIMALS; BINDING SITES; CAPSID PROTEINS; CELLS, CULTURED; DEPENDOVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HELA CELLS; HEPARIN; HUMANS; KIDNEY; MICE; MUTAGENESIS, INSERTIONAL; MUTATION; OLIGOPEPTIDES; TRANSDUCTION, GENETIC; TROPISM;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS - 2; ANIMALIA; MIRIDAE; PARVOVIRUS;

EID: 33645456779     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.353     Document Type: Article

References (29)

1. 2 antibody. Nat. Biotechnol. 17, 181-186.
2. BLEKER, S., SONNTAG, F., and KLEINSCHMIDT, J.A. (2005). Mutational analysis of narrow pores at the fivefold symmetry axes of adeno-associated virus type 2 capsids reveals a dual role in genome packaging and activation of phospholipase A2 activity. J. Virol. 79, 2528-2540.
3. BOWLES, D.E., RABINOWITZ, J.E., and SAMULSKI, R.J. (2003). Marker rescue of adeno-associated virus (AAV) capsid mutants: A novel approach for chimeric AAV production. J. Virol. 77, 423-432.
4. CHEN, S., KAPTURCZAK, M., LOILER, S.A., ZOLOTUKHIN, S., GLUSHAKOVA, O.Y., MADSEN, K.M., SAMULSKI, R.J., HAUSWIRTH, W.W., CAMPBELL-THOMPSON, M., BERNS, K.I., FLOTTE, T.R., ATKINSON, M.A., TISHER, C.C., and AGARWAL, A. (2005). Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors. Hum. Gene Ther. 16, 235-247.
5. CLARK, K.R., LIU, X., MCGRATH, J.P., and JOHNSON, P.R. (1999). Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum. Gene Ther. 10, 1031-1039.
6. CLARK, K.R., VOULGAROPOULOU, F., and JOHNSON, P.R. (1996). A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors. Gene Ther. 3, 1124-1132.
7. DAVIS, A., STACHLER, M., SHI, W., LIU, J., BOULIS, N., and BARTLETT, J. (2005). Manipulating AAV2 tropism for enhanced delivery of AAV vectors to the spinal cord. Presented at the 8th Annual Meeting of the American Society of Gene Therapy, June 1-5, 2005, St. Louis, MO. Abstract 113.
8. DING, Z., GEORGIEV, P., and THONY, B. (2005). Liver-directed, AAV- and lentivirus-mediated gene therapy in the phenylketonuria mouse model Pah-enu2. Presented at the 8th Annual Meeting of the American Society of Gene Therapy, June 1-5, 2005, St. Louis, MO. Abstract 898.
9. DOUAR, A.M., POULARD, K., and DANOS, O. (2003). Deleterious effect of peptide insertions in a permissive site of the AAV2 capsid. Virology 309, 203-208.
10. GIROD, A., RIED, M., WOBUS, C., LAHM, H., LEIKE, K., KLEINSCHMIDT, J., DELEAGE, G., and HALLEK, M. (1999). Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat. Med. 5, 1052-1056.
11. GOODMAN, S., XIAO, X., DONAHUE, R.E., MOULTON, A., MILLER, J., WALSH, C., YOUNG, N.S., SAMULSKI, R.J., and NIENHUIS, A.W. (1994). Recombinant adeno-associated virus-mediated gene transfer into hematopoietic progenitor cells. Blood 84, 1492-1500.
12. GRAHAM, F.L., SMILEY, J., RUSSELL, W.C., and NAIRN, R. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-74.
13. GRIMM, D., KERN, A., PAWLITA, M., FERRARI, F., SAMULSKI, R., and KLEINSCHMIDT, J. (1999). Titration of AAV-2 particles via a novel capsid ELISA: Packaging of genomes can limit production of recombinant AAV-2. Gene Ther. 6, 1322-1330.
14. KLEIN, R.L., MEYER, E.M., PEEL, A.L., ZOLOTUKHIN, S., MEYERS, C., MUZYCZKA, N., and KING, M.A. (1998). Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp. Neurol. 150, 183-194.
15. MORI, S., WANG, L., TAKEUCHI, T., and KANDA, T. (2004). Two novel adeno-associated viruses from cynomolgus monkey: Pseudotyping characterization of capsid protein. Virology 330, 375-383.
16. MURUVE, D.A., COTTER, M.J., ZAISS, A.K., WHITE, L.R., LIU, Q., CHAN, T., CLARK, S.A., ROSS, P.J., MEULENBROEK, R.A., MAELANDSMO, G.M., and PARKS, R.J. (2004). Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J. Virol. 78, 5966-5972.
17. OPIE, S.R., WARRINGTON, K.H., Jr., AGBANDJE-MCKENNA, M., ZOLOTUKHIN, S., and MUZYCZKA, N. (2003). Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J. Virol. 77, 6995-7006.
18. RABINOWITZ, J.E., XIAO, W., and SAMULSKI, R.J. (1999). Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology 265, 274-285.
19. RABINOWITZ, J.E., BOWLES, D.E., FAUST, S.M., LEDFORD, J.G., CUNNINGHAM, S.E., and SAMULSKI, R.J. (2004). Cross-dressing the virion: The transcapsidation of adeno-associated virus serotypes functionally defines subgroups. J. Virol. 78, 4421-4432.
20. SHI, W., and BARTLETT, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515-525.
21. SHI, W., ARNOLD, G.S., and BARTLETT, J.S. (2001). Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697-1711.
22. WARRINGTON, K.H., JR., GORBATYUK, O.S., HARRISON, J.K., OPIE, S.R., ZOLOTUKHIN, S., and MUZYCZKA, N. (2004). Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J. Virol. 78, 6595-6609.
23. WISTUBA, A., WEGER, S., KERN, A., and KLEINSCHMIDT, J.A. (1995). Intermediates of adeno-associated virus type 2 assembly: Identification of soluble complexes containing Rep and Cap proteins. J. Virol. 69, 5311-5319.
24. WOLF, J.K., MILLS, G.B., BAZZET, L., BAST, R.C., Jr., ROTH, J.A., and GERSHENSON, D.M. (1999). Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status. Gynecol. Oncol. 75, 261-266.
25. WU, P., XIAO, W., CONLON, T., HUGHES, J., AGBANDJE-MCKENNA, M., FERKOL, T., FLOTTE, T., and MUZYCZKA, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635-8647.
26. XIAO, X., LI, J., and SAMULSKI, R.J. (1998). Production of high-liter recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72, 2224-2232.
27. YANG, Q., MAMOUNAS, M., YU, G., KENNEDY, S., LEAKER, B., MERSON, J., WONG-STAAL, F., YU, M., and BARBER, J.R. (1998). Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy. Hum. Gene Ther. 9, 1929-1937.
28. YOU, Z., FISCHER, D.C., TONG, X., HASENBURG, A., AGUILAR-CORDOVA, E., and KIEBACK, D.G. (2001). Coxsackievirus-adenovirus receptor expression in ovarian cancer cell lines is associated with increased adenovirus transduction efficiency and transgene expression. Cancer Gene Ther. 8, 168-175.
29. ZOLOTUKHIN, S., BYRNE, B.J., MASON, E., ZOLOTUKHIN, I., POTTER, M., CHESNUT, K., SUMMERFORD, C., SAMULSKI, R.J., and MUZYCZKA, N. (1999). Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6, 973-985.